About Index Trending news
Analyze
Pricing
Trevi Therapeutics

Trevi Therapeutics

Work at Trevi Therapeutics? Add yourself to this profile

Trevi Therapeutics

Trevi Therapeutics is a drug development company founded in 2011 focused on developing Nalbuphine ER for the severe chronic itching condition known as pruritus.
Edit Profile
More info

Elsewhere

Companies in the same industry

InSphero InSphero Genocea Biosciences Genocea Biosciences Genentech Genentech AntriaBio AntriaBio AxoGen Inc. AxoGen Inc. EndoChoice EndoChoice Zymergen Inc. Zymergen Inc. Rubicon Genomics, Inc. Rubicon Genomics, Inc. Onramp BioInformatics Onramp BioInformatics Karmagenes Karmagenes

Alexa global traffic share

Twitter followers

Terms of Service API Integrations Plans & Pricing
Built with ❤︎ by Datalicious ©2017
A daughter company of TNW.
Index.co is not affiliated with Index Ventures.

Overview

Funding 3
Add info
08 Jan 2015
$15,000,000
Debt financing
Square 1 Bank, Solar capital

Solar Capital, Square 1 Bank Provide $15MM Facility to Trevi Therapeutics - News | ABL Advisor

abladvisor
06 Nov 2014
$26,000,000
Venture capital (Series B)
TPG Biotech
18 Dec 2012
$6,564,102
Venture capital